Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse ModelTaurin, Sebastien; Yang, Chieh-Hsiang; Reyes, Maria; Cho, Sungpil; Coombs, Demetrius M.; Jarboe, Elke A.; Werner, Theresa L.; Peterson, C. Matthew; Janát-Amsbury, Margit M. · International Journal of Gynecological Cancer · 2017

Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysisSemeniuk-Wojtaś, Aleksandra; Lubas, Arkadiusz; Stec, Rafał; Syryło, Tomasz; Niemczyk, Stanisław; Szczylik, Cezary · Clinical Genitourinary Cancer · 2018

Integral Role of the EGF Receptor in HGF-Mediated Hepatocyte ProliferationLawrence A Scheving; Mary C Stevenson; Jonathan M Taylormoore; Peter Traxler; William E Russell · 2002

Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitisLeung, John; Nguyen-Traxler, Ann; Lee, Erika M.; Yip, Jason S.; Weinstock, Joel V.; Chan, Walter W.; Ngo, Peter; Weinstein, Barbara J.; Bonis, Peter A. · Allergy and Asthma Proceedings · 2012

Erratum: Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitisLeung, John; Nguyen-Traxler, Ann; Lee, Erika M.; Yip, Jason S.; Weinstock, Joel V.; Chan, Walter W.; Ngo, Peter; Weinstein, Barbara J.; Bonis, Peter A. · Allergy and Asthma Proceedings · 2013

Detailed Evidence for an Unparalleled Interaction Mode between Calmodulin and Orai ProteinsTraxler, Lukas; Rathner, Petr; Fahrner, Marc; Stadlbauer, Michael; Faschinger, Felix; Charnavets, Tatsiana; Müller, Norbert; Romanin, Christoph; Hinterdorfer, Peter; Gruber, Hermann J. · Angewandte Chemie · 2017

Detailed Evidence for an Unparalleled Interaction Mode between Calmodulin and Orai ProteinsTraxler, Lukas; Rathner, Petr; Fahrner, Marc; Stadlbauer, Michael; Faschinger, Felix; Charnavets, Tatsiana; Müller, Norbert; Romanin, Christoph; Hinterdorfer, Peter; Gruber, Hermann J. · Angewandte Chemie International Edition · 2017

Sulfonylbenzoyl-nitrostyrenes: Potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinaseTraxler, Peter M.; Wacker, Oskar; Bach, Ha L.; Geissler, Johanna F.; Kump, Wilhelm; Meyer, Thomas; Regenass, Urs; Roesel, Johannes L.; Lydon, Nicholas · Journal of Medicinal Chemistry · 1991

4-(Phenylamino)pyrrolopyrimidines:  Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine KinaseTraxler, Peter M.; Furet, Pascal; Mett, Helmut; Buchdunger, Elisabeth; Meyer, Thomas; Lydon, Nicholas · Journal of Medicinal Chemistry · 1996

Sulfonamides: a patent review (2008 – 2012)Carta, Fabrizio; Scozzafava, Andrea; Supuran, Claudiu T · Expert Opinion on Therapeutic Patents · 2012

Related articlesPant, M.; Ang, L. K. · Expert Opinion on Therapeutic Patents · 2012

Annotated Patent SelectionsLee, Dongwon; Dasari, Madhuri; Erigala, Venkata; Murthy, Niren; Yu, Junhua; Dickson, Robert · Expert Opinion on Therapeutic Patents · 2007

Elastase inhibitorsExpert Opinion on Therapeutic Patents · 2004

AMPA receptor antagonistsChimirri, Alba; Gitto, Rosaria; Zappalà, Maria · Expert Opinion on Therapeutic Patents · 1999

Small molecules for stem cellsKochegarov, Andrei · Expert Opinion on Therapeutic Patents · 2009

Small molecules for bone diseasesMasuya, Keiichi; Teno, Naoki · Expert Opinion on Therapeutic Patents · 2010

Cathepsin K inhibitors, 2000 – 2004Cai, Jiaqiang; Jamieson, Craig; Moir, Jennifer; Rankovic, Zoran · Expert Opinion on Therapeutic Patents · 2005